|
1
|
Dehdashtian E, Mehrzadi S, Yousefi B,
Hosseinzadeh A, Reiter RJ, Safa M, Ghaznavi H and Naseripour M:
Diabetic retinopathy pathogenesis and the ameliorating effects of
melatonin; involvement of autophagy, inflammation and oxidative
stress. Life Sci. 193:20–33. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Yau JW, Rogers SL, Kawasaki R, Lamoureux
EL, Kowalski JW, Bek T, Chen SJ, Dekker JM, Fletcher A, Grauslund
J, et al: Global prevalence and major risk factors of diabetic
retinopathy. Diabetes Care. 35:556–564. 2012.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Wilkinson CP, Ferris FL III, Klein RE, Lee
PP, Agardh CD, Davis M, Dills D, Kampik A, Pararajasegaram R,
Verdaguer JT, et al: Proposed international clinical diabetic
retinopathy and diabetic macular edema disease severity scales.
Ophthalmology. 110:1677–1682. 2003.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Hershberger VS, Augsburger JJ, Hutchins
RK, Raymond LA and Krug S: Fibrovascular ingrowth at sclerotomy
sites in vitrectomized diabetic eyes with recurrent vitreous
hemorrhage: Ultrasound biomicroscopy findings. Ophthalmology.
111:1215–1221. 2004.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Lang GE: Diabetic macular edema.
Ophthalmologica. 227 (Suppl 1):S21–S29. 2012.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Waisbourd M, Goldstein M and Loewenstein
A: Treatment of diabetic retinopathy with anti-VEGF drugs. Acta
Ophthalmol. 89:203–207. 2011.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Nicholson BP and Schachat AP: A review of
clinical trials of anti-VEGF agents for diabetic retinopathy.
Graefes Arch Clin Exp Ophthalmol. 248:915–930. 2010.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Brown DM, Schmidt-Erfurth U, Do DV, Holz
FG, Boyer DS, Midena E, Heier JS, Terasaki H, Kaiser PK, Marcus DM,
et al: Intravitreal aflibercept for diabetic macular edema:
100-week results from the VISTA and VIVID studies. Ophthalmology.
122:2044–2052. 2015.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Ciulla TA, Amador AG and Zinman B:
Diabetic retinopathy and diabetic macular edema: Pathophysiology,
screening, and novel therapies. Diabetes Care. 26:2653–2664.
2003.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Grauslund J, Green A and Sjolie AK:
Prevalence and 25 year incidence of proliferative retinopathy among
Danish type 1 diabetic patients. Diabetologia. 52:1829–1835.
2009.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Yang X, Xu J, Wang R, Mei Y, Lei H, Liu J,
Zhang T and Zhao H: A randomized controlled trial of conbercept
pretreatment before vitrectomy in proliferative diabetic
retinopathy. J Ophthalmol. 2016(2473234)2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Tetikoglu M, Yuksel Z, Aktas S, Sagdik HM
and Ozcura F: VEGF-A gene polymorphisms and responses to
intravitreal ranibizumab treatment in patients with diabetic
macular edema. Int Ophthalmol. 38:2381–2388. 2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Mesquita J, Castro de Sousa J, Vaz-Pereira
S, Neves A, Tavares-Ratado P, M Santos F, A Passarinha L and T
Tomaz C: VEGF-B levels in the vitreous of diabetic and non-diabetic
patients with ocular diseases and its correlation with structural
parameters. Med Sci (Basel). 5(17)2017.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Ahn J, Woo SJ, Chung H and Park KH: The
effect of adjunctive intravitreal bevacizumab for preventing
postvitrectomy hemorrhage in proliferative diabetic retinopathy.
Ophthalmology. 118:2218–2226. 2011.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Yeh PT, Yang CM, Lin YC, Chen MS and Yang
CH: Bevacizumab pretreatment in vitrectomy with silicone oil for
severe diabetic retinopathy. Retina. 29:768–774. 2009.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Pan GD, Yang JQ, Yan LN, Chu GP, Liu Q,
Xiao Y and Yuan L: Reversal of multi-drug resistance by
pSUPER-shRNA-mdr1 in vivo and in vitro. World J Gastroenterol.
15:431–440. 2009.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Takahashi S: Vascular endothelial growth
factor (VEGF), VEGF receptors and their inhibitors for
antiangiogenic tumor therapy. Biol Pharm Bull. 34:1785–1788.
2011.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Yang CM, Yeh PT, Yang CH and Chen MS:
Bevacizumab pretreatment and long-acting gas infusion on vitreous
clear-up after diabetic vitrectomy. Am J Ophthalmol. 146:211–217.
2008.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Folkman J: Angiogenesis: An organizing
principle for drug discovery? Nat Rev Drug Discov. 6:273–286.
2007.PubMed/NCBI View
Article : Google Scholar
|
|
20
|
Tolentino MJ, Miller JW, Gragoudas ES,
Chatzistefanou K, Ferrara N and Adamis AP: Vascular endothelial
growth factor is sufficient to produce iris neovascularization and
neovascular glaucoma in a nonhuman primate. Arch Ophthalmol.
114:964–970. 1996.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Ferrone PJ and Jonisch J: Comparison of
ranibizumab 0.5 mg versus 1.0 mg for the treatment of patients with
clinically significant diabetic macular edema: A randomized,
clinical trial. Ophthalmic Surg Lasers Imaging Retina. 47:536–543.
2016.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Dong F, Yu C, Ding H, Shen L and Lou D:
Evaluation of intravitreal ranibizumab on the surgical outcome for
diabetic retinopathy with tractional retinal detachment. Medicine
(Baltimore). 95(e2731)2016.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Arevalo JF, Lasave AF, Kozak I, Al Rashaed
S, Al Kahtani E, Maia M, Farah ME, Cutolo C, Brito M, Osorio C, et
al: Preoperative bevacizumab for tractional retinal detachment in
proliferative diabetic retinopathy: A prospective randomized
clinical trial. Am J Ophthalmol. 207:279–287. 2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Zhang F, Tang Z, Hou X, Lennartsson J, Li
Y, Koch AW, Scotney P, Lee C, Arjunan P, Dong L, et al: VEGF-B is
dispensable for blood vessel growth but critical for their
survival, and VEGF-B targeting inhibits pathological angiogenesis.
Proc Natl Acad Sci USA. 106:6152–6157. 2009.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Zhong X, Huang H, Shen J, Zacchigna S,
Zentilin L, Giacca M and Vinores SA: Vascular endothelial growth
factor-B gene transfer exacerbates retinal and choroidal
neovascularization and vasopermeability without promoting
inflammation. Mol Vis. 17:492–507. 2011.PubMed/NCBI
|
|
26
|
Puddu A, Sanguineti R, Traverso CE,
Viviani GL and Nicolo M: Response to anti-VEGF-A treatment of
retinal pigment epithelial cells in vitro. Eur J Ophthalmol.
26:425–430. 2016.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Puddu A, Sanguineti R, Traverso CE,
Viviani GL and Nicolo M: Response to anti-VEGF-A treatment of
endothelial cells in vitro. Exp Eye Res. 146:128–136.
2016.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Wafai R, Tudor EM, Angus JA and Wright CE:
Vascular effects of FGF-2 and VEGF-B in rabbits with bilateral hind
limb ischemia. J Vasc Res. 46:45–54. 2009.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Rissanen TT, Markkanen JE, Gruchala M,
Heikura T, Puranen A, Kettunen MI, Kholová I, Kauppinen RA, Achen
MG, Stacker SA, et al: VEGF-D is the strongest angiogenic and
lymphangiogenic effector among VEGFs delivered into skeletal muscle
via adenoviruses. Circ Res. 92:1098–1106. 2003.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Zhang X, Wu J, Wu C, Bian AL, Geng S and
Dai RP: Comparison of aqueous humor levels of PlGF and VEGF in
proliferative diabetic retinopathy before and after intravitreal
conbercept injection. Diabetes Res Clin Pract.
162(108083)2020.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Torres-Soriano ME, Reyna-Castelan E,
Herna´ndez-Rojas M, Garcıa-Aguirre G, Kon-Jara V, Diaz-Rubio JL,
Guerrero-Naranjo JL, Jimenez-Sierra JM and Quiroz-Mercado H:
Tractional retinal detachment after intravitreal injection of
bevacizumab in proliferative diabetic retinopathy. Retin Cases
Brief Rep. 3:70–73. 2009.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Simo R, Sundstrom JM and Antonetti DA:
Ocular Anti-VEGF therapy for diabetic retinopathy: The role of VEGF
in the pathogenesis of diabetic retinopathy. Diabetes Care.
37:893–899. 2014.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Spilsbury K, Garrett KL, Shen WY,
Constable IJ and Rakoczy PE: Overexpression of vascular endothelial
growth factor (VEGF) in the retinal pigment epithelium leads to the
development of choroidal neovascularization. Am J Pathol.
157:135–144. 2000.PubMed/NCBI View Article : Google Scholar
|
